Relugolix for treating hormone-sensitive prostate cancer

Relugolix (Orgovyx, Accord) is indicated for:

• 'the treatment of adult patients with advanced hormone-sensitive prostate cancer'

• 'the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy'

• 'neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer'.

The dosage schedule is available in the summary of product characteristics for relugolix.

The list price for relugolix is £87.45 (excluding VAT; dictionary of medicines and devices, accessed August 2024) for a 30‑pack of 120‑mg tablets.

Costs may vary in different settings because of negotiated procurement discounts.